Background Emerging fungal pathogens pose important threats to global public health. The
World Health Organization has responded to the rising threat of traditionally neglected …

Cellulitis, an infection involving the deep dermis and subcutaneous tissue, is the most
common reason for skin-related hospitalization and is seen by clinicians across various …

Ruxolitinib, a selective inhibitor of Janus kinases, is a standard treatment for
intermediate/high-risk myelofibrosis (MF) but is associated with a predisposition to …

Scope Consuming goat milk is known to benefit high‐fat diet‐fed and streptozocin (STZ)‐
induced diabetic rats, but the underlying mechanisms are unknown. This study is conducted …

Background: The Janus kinase (JAK) 1/2 inhibitor ruxolitinib has been approved in an
indication of myelofibrosis and is a candidate for the treatment of a number of inflammatory …

Highlights•Ruxolitinib, the first Janus kinase inhibitor approved, is highly
immunomodulatory.•Pacritinib, a novel Janus kinase inhibitor, exhibits only mild suppressive …

Cryptococcal meningoencephalitis is a systemic fungal infection in immunocompromised
and immunocompetent individuals. This study investigated the clinical characteristics and …

Mycobacterium haemophilum (MH) ist ein langsam wachsendes, nicht‐tuberkulöses
Mykobakterium. Infektionen treten am häufigsten bei Patienten mit beeinträchtigtem …

Mycobacterium haemophilum (MH) is a slow‐growing, non‐tuberculous Mycobacterium that
most commonly causes infections in immunocompromised patients. The skin is the most …

With an advance in therapy, there are increasing emerging and re-emerging opportunistic
infections among patients with hematologic conditions and malignancy. Herein, we present …